Ophthalmology

However, vision is no longer significantly improved after 4 years of using anti-VEGF therapies.

After implantation, investigators observed very good distance, intermediate and near functional visual outcomes and a high percentage of subjects without visual disturbances.

The investigators labeled pre-existing glaucoma, high preoperative intraocular pressure, and combined keratoplasty with removal or exchange of an intraocular lens were definitely associated with an increased risk.

Investigators presented the study at the Netherlands Ophthalmological Society Annual Congress, noting a potential cause for this trend could be the heightened cautiousness of surgical teams following the 2 month intermission due to the COVID-19 pandemic.

At 12 months, the mean VA change from baseline was 17.6 for BRVO patients and 18.6 for CRVO patients in the Netherlands.

The eyelid maneuvers increased intraocular pressure by ≥40mm Hg in patients with primary open-angle glaucoma.

Patients with RVO in a nationwide cohort in Denmark had an increased risk to develop overall, ischemic and non-ischemic CVD compared to non-RVO control patients.

A deep learning system provided accurate predictions of occurrence and severity of ROP ≤45 weeks’ PMA based on retinal photographs at first screening.

Combination treatment was equal to anti-VEGF monotherapy in functional and structural outcomes in the treatment of macular edema due to BRVO.

Patients with diabetic retinopathy showed significantly higher updated first-year HbA1c and at follow-up compared to those free from DR.

Thinning across the PMB associated with poorer VA at 9 months’ corrected age, independent of gestational age and macular microanatomy.

The study authors suggest a thinner macular RNFL may predict a decline in cognitive performance.

The NDA submission is based on results from the Phase 3 DERBY and OAKS studies and the Phase 2 FILLY study.

The meta-analysis included more than 11,000 patients with between 8 and 9 years of mean follow-up periods.

In the first episode of this new game show, a team of ARVO 2022 investigators work to invent an innovative clinical trial.

From curative stem cell approaches to in-clinic subretinal injections, Arshad Khanani, MD, MA, navigates what the future drug class may entail.

An FDA decision could come as soon as this year. One expert stresses the need for improved screening, biomarker research, and patient communication beforehand.

Early-stage prevention of modifiable risk factors may contribute to the prevention of neurodegenerative changes and diabetic retinopathy.

Study author Arshad Khanani, MD, MA, discusses how the novel-targeting gene therapy candidate may uniquely benefit patients with treated retina disease.

Theodore Leng, MD, MS, discusses his team's IRIS registry findings suggesting a need for quantifying how vision-loss patients are impacted by functional or quality-of-life measures.

Data show half of all eyes with CRVO were still being treated at 36-months.

Treatment delay and steroid usage were both associated with worse improvements in long term BVA and CST in patients with RVO-related macular edema.

Veeral S. Sheth, MD, MBA, gives an update on his practice's adoption of the novel PDS in patients with AMD—and discusses other potential methods of anti-VEGF delivery.

These data further elucidate the relationship between mental health and diabetic retinopathy.

However, data show RVO patients with clinical findings associated with glaucoma risk are often not coded with suspected glaucoma.

A new assessment from ARVO 2022 showed methodology to predict one-year treatment response to treat-and-extend ranibizumab at 1 year.

The study agent was otherwise not associated with an increased number of intravitreal injections over a 12-month period.

Veeral S. Sheth, MD, MBA, discusses promising agents in development for geographic atrophy and other under-addressed ophthalmic diseases.

Patients with DR had an average interval between anti-VEGF injections of 70 days, compared to 54 days for RVO patients and 55 days for wetAMD patients.

One researcher suggests the supplement may serve as an add-on measurement against AMD progression in early-stage patients.